Clinical Trial Search

Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants

Primary: Percentage of Patients Who Complete Neoadjuvant Therapy and Were Eligible for Curative Surgical Resection — 16 Participants

Primary: Overall Response Rate — 11; 1; 10 Participants — p=0.0005

Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events

Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants

Primary: Overall Response Rate (ORR) by Independent Central Review — 50.8; 44.9; 46.4; 61.9 percentage of participants

Primary: Percentage of Participants With Local Regional Control — 91.1 percentage of subjects

Primary: Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review — 40 Participants

Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750

Primary: Recurrence-Free Survival (RFS) as Assessed by the Investigator and Confirmed by Biopsy — 53.3; 53.7 Months — p=0.07243

Primary: Number of Participants With Adverse Events — 10; 4; 1; 20 Participants

Primary: Number of Participants With Objective Response (Partial Response, Stable Disease and Progressive Disease) — 14; 4; 19 participants

Primary: Objective Response Rate (ORR) — 35.2; 51.9 Percentage of participants

Primary: Rate of Renal Transplant Rejection (Cohort 2) or GVHD (Cohort 1). — 0 Percentage of participants

Primary: Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE — 7; 9; 4; 2 score on a scale

Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions

Primary: Response Rate of Cetuximab by RECIST Criteria — 15 Participants

Primary: Cure Rate — 751 lesions

Primary: Early Progression Rate — 31.8 percentage of participants

Primary: Number Participants With 100% Clearance — 12; 13 Participants

Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120

Primary: Incidence of SCC — 3.1; 0.4 percentage of subjects

Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants

Primary: The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed — 3.37; 3.52 years — p=0.93

Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors

Primary: Number of Control and Intervention Participants on Skin Self-examination Performance at Follow-up 1 Month After Intervention — 34; 8 Participants

Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants

Primary: Pathologic Response. — 25; 2; 4; 4 Participants

Primary: Overall Response Rate — 69.7 percentage of tumor lesions

Primary: Overall Response Rate — 3 Participants